MCAC Panel Decision Postponed Following Chair's "No Confidence" Vote
This article was originally published in The Gray Sheet
Executive Summary
A dissenting opinion by Medicare Coverage Advisory Committee's Drugs, Biologics, and Therapeutics Panel Chair Thomas Holohan, MD, Department of Veterans Affairs, effectively nullified a unanimous recommendation by his panel supporting coverage of stem cell transplantation for multiple myeloma.
You may also be interested in...
MCAC Panel Process Concerns Derail Ratification Of Initial Coverage Opinions
Standard procedures for conducting Medicare Coverage Advisory Committee panel reviews must be developed if future panel recommendations are to hold any chance of ratification, several members of MCAC's Executive Committee maintained at a Dec. 8 meeting.
MCAC Panel Process Concerns Derail Ratification Of Initial Coverage Opinions
Standard procedures for conducting Medicare Coverage Advisory Committee panel reviews must be developed if future panel recommendations are to hold any chance of ratification, several members of MCAC's Executive Committee maintained at a Dec. 8 meeting.
MCAC Panel Recommends Medicare Coverage For Stem Cell Therapy
Autologous stem cell transplantation (ASCT) in combination with high dose chemotherapy should receive Medicare coverage for treatment of multiple myeloma, the Drugs, Biologics and Therapeutics Panel of the Medicare Coverage Advisory Committee unanimously recommended Sept. 16 in a 5-0 vote.